Bellevue Group’s Novo Nordisk NVO Stock Holding History

Bellevue Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,500	Closed	-$449K	–	155
2025 Q2	$449K	Buy	+6,500	New	+$442K	0.01%	109

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bellevue Group's NVO Position: Q3 2025 in Review

Bellevue Group sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 6,500 shares — an estimated $449K sold.

Bellevue Group first reported a position in NVO in Q2 2025 and held it in 1 quarter. The position peaked at $449K in Q2 2025. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Bellevue Group reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Bellevue Group sold 6,500 Novo Nordisk shares in Q3 2025, an estimated $449K.
Bellevue Group first reported a position in Novo Nordisk in Q2 2025 and held it in 1 quarter.
Bellevue Group's Novo Nordisk position peaked at $449K in Q2 2025.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.